|Table of Contents|

Expression and clinical significance of serum IL-6 and IL-10 in patients with non-Hodgkin' s lymphoma

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2022 06
Page:
1076-1079
Research Field:
Publishing date:

Info

Title:
Expression and clinical significance of serum IL-6 and IL-10 in patients with non-Hodgkin' s lymphoma
Author(s):
SHEN Jing1; ZHANG Yongchao2; YANG Ronghui3; YANG Wei1
1.Department of Hematology;2.Hematology Laboratory，Shengjing Hospital of China Medical University，Liaoning Shenyang 110004，China;3.Department of Blood Transfusion,China Medical University First Hospital,Liaoning Shenyang 110004，China．
Keywords:
IL-6; IL-10; non-Hodgkin's lymphoma
PACS:
R733.4
DOI:
10.3969/j.issn.1672-4992.2022.06.026
Abstract:
Objective:To determine the change and clinical significance of IL-6 and IL-10 serum level in non-Hodgkin's lymphoma(NHL) patients and their relationship with clinical features and prognosis.Methods:The medical records of 278 patients between June 2013 and June 2016 for NHL were retrospectively analysed.The serum levels of IL-6 and IL-10 in patients were retrospectively analyzed.Results:The serum levels of IL-6 and IL-10 in NHL patients were significantly higher than those in the control group.According to the different clinical characteristics of the group,it can be seen that the serum levels of IL-6 and IL-10 had no significant correlation with gender and age.However,when there were the high levels of stage,IPI score,CRP,LDH,serum β2 microglobulin，symptom B and bone marrow invasion,the serum levels of IL-6 and IL-10 were significantly higher in patients(P<0.001).According to the efficacy group,patients with better efficacy had lower levels of IL-6 and IL-10 at the beginning of the disease.While patients with poor efficacy had higher levels of IL-6 and IL-10 at the beginning of the disease.After remission,the indicators can be reduced to normal.The indicators of IL-6 and IL-10 remained unchanged or increase if there was no remission.Conclusion:The increase of IL-6 and IL-10 in patients with NHL is a predictor of severe clinical symptoms and poor prognosis.

References:

［1］SHINWAN K,JAN TV,BORNA R.Cytokines in inflammatory disease［J］.International Journal of Molecular Sciences,2019,20(23):6008.
［2］ CHEN X，WANG L，WANG W，et al.B7-H4 facilitates proliferation of esophageal squamous cell carcinoma cells through promoting interleukin-6/signal transducer and activator of transcription 3 pathway activation［J］.Cancer Science,2016,107(7):944-954.
［3］KURZROCK R,VOORHEES PM,CASPER C,et al.A phase I,open-label study of siltuximab,an anti-IL-6 monoclonal antibody,in patients with B-cell non-Hodgkin's lymphoma,multiple myeloma,or castleman's disease［J］.Clinical Cancer Research,2013,19(13):3659-3670.
［4］NACINOVIC-DULETIC A,TIFTER S,DVORNIK ,et al.(2008) Correlation of serum IL-6,IL-8 and IL-10 levels with clinicopathological features and prognosis in patients with diffuse large B-cell lymphoma［J］.International Journal of Laboratory Hematology,2008,30(3):230-239.
［5］ROSE JS.Interleukin-6 family cytokines［J］.Cold Spring Harbor Perspectives in Biology,2018，10(2):a028415.
［6］ CHEN Z，YOU L，WANG L，et al.Dual effect of DLBCL derived EXOs in lymphoma to improve DC vaccine efficacy in vitro while favor tumorgenesis in vivo［J］.Journal of Experimental & Clinical Cancer Research,2018,37(1):190.
［7］ CHEN X，WANG W，MAN H，et al.Increased B7-H4 expression during esophageal squamous cell carcinogenesis is associated with IL-6/STAT3 signaling pathway activation in mice［J］.Oncol Letter,2017,13(4):2207-2215.
［8］NDEDE I，MINING SK，PATEL K，et al.Cytokines associated with Burkitt's lymphoma in western Kenya［J］.BMC Research Notes,2017,10(1):519.
［9］ OHNO Y,TOYOSHIMA Y,YURINO H,et al.Lack of interleukin-6 in the tumor microenvironment augments type-1 immunity and increases the efficacy of cancer immunotherapy［J］.Cancer Science,2017，108(10)：1959-1966.
［10］李萍，刘馨，刘洪璐，等.癌相关性炎症因子IL-6在肿瘤微环境中的作用研究进展［J］.现代肿瘤医学，2017,25（19）：3174-3177. LI Ping，LIU Xin，LIU Honglu，et al.The cancer-associated inflammatory cytokine IL-6 plays roles in tumor microenvironment［J］.Modern Oncology,2017,25（19）：3174-3177.
［11］WANG L,ZHAO Y,QIAN J,et al.toll-like receptor-4 signaling in mantle cell lymphoma effects on tumor growth and immune evasion［J］.Cancer,2012,119(4):782-791.
［12］ BARTSCH R,WOEHRER S,RADERER M,et al.Serum interleukin-6 levels in patients with gastric MALT lymphoma compared to gastric and pancreatic cancer［J］.Anticancer Research,2006,26(4B):3187-3190.
［13］ SONG Y,ZHANG W,ZHANG L,et al.Cerebrospinal fluid IL-10 and IL-10/IL-6 as accurate diagnostic biomarkers for primary central nervous system large B-cell lymphoma［J］.Scientific Reports,2016,6(1):38671.
［14］ MOCELLIN S,MARINCOLA FM,YOUNG HA.Interleukin-10 and the immune response against cancer:a counterpoint［J］.Journal of Leukocyte Biology,2005,78(5):1043-1051.
［15］HAMIDULLAH CB,KONWAR R.Role of interleukin-10 in breast cancer［J］.Breast Cancer Research and Treatment,2012，133(1):11-21.
［16］MISSOTTEN T,TIELEMANS D,BROMBERG JE,et al.multicolor flowcytometric immunophenotyping is a valuable tool for detection of intraocular lymphoma［J］.Ophthalmology,2013,120(5):991-996.
［17］BEAULOYE,VERONIQUE,STEFFENS,et al.Characterization of insulin resistance in young adult survivors of childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma［J］.Clinical Endocrinology,2013,78(5):790-798.

Memo

Memo:
-
Last Update: 1900-01-01